{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:43:49Z","timestamp":1793853829202,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":6058,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1111\/j.1600-6143.2006.01288.x","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T10:47:18Z","timestamp":1142851638000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":525,"special_numbering":"P1","title":["Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action"],"prefix":"10.1016","volume":"6","author":[{"given":"M.D.","family":"Pescovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1600-6143.2006.01288.x_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000235503","article-title":"Humoral transplantation antibodies play a role in protracted rejection of murine renal allografts.","volume":"96","author":"Inoue","year":"1991","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0041-1345(98)02060-0","article-title":"Humoral transplantation antibodies.","volume":"31","author":"Milgrom","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.humimm.2005.01.021","article-title":"Humoral theory of transplantation: Mechanism, prevention, and treatment.","volume":"66","author":"Cai","year":"2005","journal-title":"Hum Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin.","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib5","first-page":"119a","article-title":"Interferon-g induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells.","volume":"94","author":"Treon","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.","volume":"7","author":"Einfeld","year":"1988","journal-title":"Embo J"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 in patients with recurrent B-cell lymphoma.","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) in relapsed B-cell lymphoma.","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.","volume":"45","author":"Ng","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"issue":"Suppl III","key":"10.1111\/j.1600-6143.2006.01288.x_bib14","first-page":"434","article-title":"Primary analysis of a double-blind, placebo-controlled, dose-ranging trial of rituximab, an anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis receiving methotrexate (DANCER TRIAL).","volume":"64","author":"Emery","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.transproceed.2004.12.066","article-title":"New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies.","volume":"37","author":"Book","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jim.2005.03.001","article-title":"Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing.","volume":"300","author":"Bearden","year":"2005","journal-title":"J Immunol Methods"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib17","first-page":"637","article-title":"The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin\u2019s lymphoma (NHL) cell lines.","volume":"88","author":"Maloney","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib19","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev.immunol.23.021704.115728","article-title":"Marginal zone B cells.","volume":"23","author":"Pillai","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00281-004-0190-2","article-title":"B cell superantigens: A microbe\u2019s answer to innate-like B cells and natural antibodies.","volume":"26","author":"Goodyear","year":"2005","journal-title":"Springer Semin Immunopathol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib23","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.4049\/jimmunol.134.6.3656","article-title":"Studies on the induction of tolerance to alloantigens I. The abrogation of potentials for delayed-type-hypersensitivity responses to alloantigens by portal venous inoculation with allogeneic cells.","volume":"134","author":"Qian","year":"1985","journal-title":"J Immunology"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib24","first-page":"397","article-title":"Effective B-cell depletion in peripheral blood and tissue by single-dose rituximab in kidney transplant recipients: A pilot study.","volume":"5","author":"Genberg","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0966-3274(03)00059-5","article-title":"Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.","volume":"12","author":"Schroder","year":"2003","journal-title":"Transpl Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib26","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","article-title":"In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.","volume":"13","author":"Sidner","year":"2004","journal-title":"Hum Antibodies"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007890-200201150-00019","article-title":"Treatment of posttransplant lymphoproliferative disease with rituximab: The remission, the relapse, and the complication.","volume":"73","author":"Verschuuren","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes.","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1600-6143.2004.00502.x","article-title":"Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses.","volume":"4","author":"Agarwal","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.healun.2004.01.006","article-title":"Use of rituximab to decrease panel-reactive antibodies.","volume":"24","author":"Balfour","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1399-0012.1992.tb00615.x","article-title":"OKT3 treatment of acute renal allograft rejection in children.","volume":"6","author":"Pescovitz","year":"1992","journal-title":"Clin Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib34","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","article-title":"Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.","volume":"345","author":"Suzan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab.","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib36","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib37","first-page":"1239","article-title":"Immunomodulatory impact of rituximab and thymoglobuin therapy in liver transplantation.","volume":"5","author":"Agarwal","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2003-03-1005","article-title":"No clinical evidence for CD4+ cell depletion caused by rituximab.","volume":"102","author":"Saville","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib39","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness.","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/clim.2000.4980","article-title":"Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).","volume":"98","author":"Gonzalez-Stawinski","year":"2001","journal-title":"Clinical Immunology"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","article-title":"Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.","volume":"5","author":"Bearden","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1385\/MO:21:3:273","article-title":"Posttransplant lymphoma\u2013a single-center experience of 500 liver transplantations.","volume":"21","author":"Norin","year":"2004","journal-title":"Med Oncol"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib43","first-page":"360","article-title":"Post-transplant lymphoproliferative disorders (PTLD) in kidney transplantation: Report of 220 cases of a French registry.","volume":"5","author":"Caillard","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1517\/14728214.7.2.289","article-title":"Rituximab and other emerging monoclonal antibody therapies for lymphoma.","volume":"7","author":"Tobinai","year":"2002","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007890-200108150-00010","article-title":"Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients.","volume":"72","author":"Luke","year":"2001","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20192-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins.","volume":"9","author":"Basta","year":"2003","journal-title":"Nature Med"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib47","first-page":"324","article-title":"Measurement of HLA antibody specificity by single antigen beads and MESF quatitation demonstrates efficacy of rituximab desensitization.","volume":"5","author":"Pescovitz","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","article-title":"Long-lived plasma cells: A mechanism for maintaining persistent antibody production.","volume":"10","author":"Slifka","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells.","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib50","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells.","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib51","first-page":"2836","article-title":"CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.","volume":"63","author":"Lapointe","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib52","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/intimm\/13.12.1583","article-title":"Role of B cells as antigen-presenting cells in vivo revisited: Antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.","volume":"13","author":"Rivera","year":"2001","journal-title":"Int Immunol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa035588","article-title":"Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.","volume":"349","author":"Sarwal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib54","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/j.1600-6143.2005.01009.x","article-title":"Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.","volume":"5","author":"Hippen","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1399-0012.2004.00292.x","article-title":"Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.","volume":"19","author":"Alausa","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","article-title":"Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.","volume":"28","author":"Vugmeyster","year":"2005","journal-title":"J Immunother"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation.","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib58","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1517\/14712598.5.1.S61","article-title":"Molecules involved in T-B co-stimulation and B cell homeostasis: Possible targets for an immunological intervention in autoimmunity.","volume":"5","author":"Peter","year":"2005","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/11.suppl_1.S113","article-title":"Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients.","volume":"11","author":"Milpied","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib60","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/08880010390203125","article-title":"Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20-positive large B-Cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.","volume":"20","author":"Culic","year":"2003","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1034\/j.1399-3046.2003.00024.x","article-title":"Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child.","volume":"7","author":"Bueno","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib62","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S1053-2498(02)00439-4","article-title":"Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.","volume":"21","author":"Herman","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib63","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00007890-200210150-00018","article-title":"Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.","volume":"74","author":"Berney","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib64","first-page":"389","article-title":"Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.","volume":"34","author":"Serinet","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib65","first-page":"469","article-title":"Anti-CD20 monoclonal antibody (rituximab) for pediatric post-transplant lymphoproliferative disorders: A preliminary multicenter experience.","volume":"1","author":"Webber","year":"2001","journal-title":"Am J Transplant"},{"issue":"Suppl","key":"10.1111\/j.1600-6143.2006.01288.x_bib66","first-page":"S3331","article-title":"CD20 ligation using rituximab (anti-CD20 monoclonal antibody) inhibits growth of EBV infected B cells from a patient with PTLD.","volume":"69","author":"Chen","year":"2000","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib67","first-page":"246b","article-title":"Anti-CD20 monoclonal antibody (rituximab) for post-transplant lymphoproliferative disease treatment (PTLD).","volume":"96","author":"Roithmann","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib68","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1053-2498(00)00326-0","article-title":"Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.","volume":"20","author":"Zilz","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib69","first-page":"618","article-title":"Anti-CD20 antibody rituximab administration in patients with late-occurring lymphomas after solid organ transplant.","volume":"86","author":"Dotti","year":"2001","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib70","first-page":"284a","article-title":"Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: A prospective trial in adults and children.","volume":"20","author":"Horwitz","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib71","first-page":"287","article-title":"Lymphocyte subsets may discern treatment effects in children with post-transplant lymphoproliferative disorder (PTLD).","volume":"1","author":"Ganjoo","year":"2001","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"10.1111\/j.1600-6143.2006.01288.x_bib72","first-page":"311","article-title":"Thymoglobulin (T) in the management of steroid resistant acute cellular rejection (SRACR) in children.","volume":"1","author":"Mazariegos","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1397-3142.2003.00135.x","article-title":"The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.","volume":"8","author":"Pescovitz","year":"2004","journal-title":"Pediatr Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib74","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/j.1600-6143.2005.01098.x","article-title":"Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).","volume":"5","author":"Oertel","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib75","unstructured":"Choquet S Leblond V Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase II study. Blood 2005."},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib76","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.transproceed.2004.12.114","article-title":"New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange.","volume":"37","author":"Kawagishi","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib77","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1600-6143.2004.00507.x","article-title":"Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.","volume":"4","author":"Sonnenday","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0012.2004.00151.x","article-title":"Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation.","volume":"18","author":"Sawada","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-6143.2004.00653.x","article-title":"ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.","volume":"5","author":"Tyden","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.TP.0000149337.40911.E4","article-title":"Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation.","volume":"79","author":"Usuda","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib81","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1600-6143.2005.01031.x","article-title":"ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment.","volume":"5","author":"Segev","year":"2005","journal-title":"Am J Transplant"},{"issue":"Supp 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib82","first-page":"183","article-title":"Successful ABO-incompatible kidney transplantation for non-responders with the use of anti-CD20 monoclonal antibody and plasmapheresis.","volume":"5","author":"Koyama","year":"2005","journal-title":"Am J Transplant"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib83","first-page":"324","article-title":"Successful kidney transplant in ABO incompatible patients after plasmapheresis and thymoglobulin under a steroid avoidance protocol.","volume":"5","author":"Diaz","year":"2005","journal-title":"Am J Transplant"},{"issue":"Suppl 5","key":"10.1111\/j.1600-6143.2006.01288.x_bib84","first-page":"200","article-title":"Living donor kidney transplantation in positive crossmatch patients.","volume":"3","author":"Gloor","year":"2003","journal-title":"Am J Transplant"},{"issue":"Suppl 3","key":"10.1111\/j.1600-6143.2006.01288.x_bib85","first-page":"259","article-title":"Early allograft outcomes in patients with antibody mediated rejection treated with rituximab.","volume":"2","author":"Samaniego","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib86","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0003-4975(02)03824-9","article-title":"Treatment of humoral rejection with rituximab.","volume":"74","author":"Garrett","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib87","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/00007890-200203270-00013","article-title":"Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: A case report.","volume":"73","author":"Aranda","year":"2002","journal-title":"Transplantation"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib88","first-page":"397","article-title":"Rituximab rescue for refractory antibody mediated rejection after kidney transplantation.","volume":"5","author":"Goldstein","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib89","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","article-title":"Rituximab as treatment for refractory kidney transplant rejection.","volume":"4","author":"Becker","year":"2004","journal-title":"Am J Transplant"},{"issue":"Suppl 11","key":"10.1111\/j.1600-6143.2006.01288.x_bib90","first-page":"292","article-title":"Achieving desensitization and preventing humoral rejection in positive crossmatch living donor kidney transplantation.","volume":"5","author":"Stegall","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2006.01288.x_bib91","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","article-title":"Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.","volume":"20","author":"Nozu","year":"2005","journal-title":"Pediatr Nephrol"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-6143.2006.01288.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522026636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522026636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-6143.2006.01288.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:38:12Z","timestamp":1761626292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522026636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S1600613522026636"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01288.x","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01288.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}